Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9QC07
UPID:
POK18_HUMAN
Alternative names:
HERV-K(C1a) Pol protein; HERV-K110 Pol protein; HERV-K18 Pol protein; HERV-K_1q23.3 provirus ancestral Pol protein
Alternative UPACC:
Q9QC07; Q6QAI9; Q96PI5
Background:
The Endogenous retrovirus group K member 18 Pol protein, with alternative names such as HERV-K(C1a) Pol protein and HERV-K110 Pol protein, plays a crucial role in the early post-infection stage. It converts viral RNA into double-stranded DNA, with its RNase H domain degrading the RNA template and removing the RNA primer. This protein is also involved in the integration of viral DNA into the host cell chromosome.
Therapeutic significance:
Understanding the role of Endogenous retrovirus group K member 18 Pol protein could open doors to potential therapeutic strategies.